Zheng Quan Zhi Xing·2025-08-26 16:23Core Points - The board of directors of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. held its eighth meeting of the tenth session on August 26, 2025, to review and approve several key reports and proposals [1][2][3] Group 1: Financial Reports - The board approved the 2025 semi-annual report of the group, which was prepared in accordance with relevant laws and regulations in China [1][2] - The internal control evaluation report for the first half of 2025 was also approved, having been recognized by the audit committee prior to the board meeting [2] - A special report on the storage and actual use of raised funds for the first half of 2025 was approved [2] Group 2: Risk Assessment and Strategic Planning - The board approved a risk assessment report regarding Shanghai Fosun High Technology Group Financial Co., Ltd., with the proposal recognized by independent non-executive directors before the meeting [3][7] - The board also approved the semi-annual evaluation report for the "Quality Improvement and Efficiency Enhancement" initiative [3] - The long-term strategic plan for 2025-2035 was approved [3] Group 3: Agreements and Frameworks - The board approved the renewal of the product/service mutual supply framework agreement with Sinopharm Holding Co., Ltd., which requires shareholder approval [3][5] - A financial services agreement renewal with Shanghai Fosun High Technology Group Financial Co., Ltd. was also approved, pending shareholder approval [6][7] - The board agreed to a licensing agreement with Sitala Bio Ltd. for the development and commercialization of specific products outside of China [8][9] Group 4: Shareholder Meeting - The board approved the convening of the first extraordinary general meeting of 2025, with details to be announced later [9]